Skip to main content
Premium Trial:

Request an Annual Quote

NCI Awards Burnham Institute $9.5M to Find Prostate Cancer s Molecular Signature

NEW YORK, Dec. 15 (GenomeWeb News) - With funding from the National Cancer Institute, the Burnham Institute for Medical Research will collaborate on a task force to define molecular signatures for prostate cancer, the not-for-profit research institution said today.


The consortium, led by University of California, Irvine will receive $9.5 million over the next five years.


In its tissue microarray analyses of 4,000 prostate tissue samples, the group will look for cancer markers that are indicative of the clinical behavior of prostate cancer cells, the institute said.


Other collaborating institutions include University of California, San Diego; Northwestern University; the Translation Genomic Institute of Phoenix; San Diego, Calif.-based Sidney Kimmel Cancer Center; and the Sun Health Research Institute.


The NCI funding is part of its Strategic Partnering to Evaluate Cancer Signatures Program. In addition to prostate cancer, NCI awarded funding for childhood leukemias, non-Hodgekin's lymphoma, lymphocytic leukemia, lung cancer, and breast cancer.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.